Entropy Neurodynamics is an Australian biotechnology company focused on developing novel therapies for neurological and psychiatric disorders. They leverage innovative approaches in drug development, aiming to address unmet needs in mental health and improve patient outcomes. The company is listed on the ASX and seeks to create value through its research and development pipeline.
Entropy Neurodynamics (ASX:ENP) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 6 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. ENP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Latest articles and price-sensitive announcements with AI sentiment classification.
ENP says the first patient of its Cohort 2 Phase II BED trial was dosed with TRP-8803 on October 5 ... Read More The post Entropy starts 60-minute IV psilocin dosing in phase II binge-eating trial appeared first on Stockhead.
other announcement
other announcement
other announcement
Professor unpacks the 12-week results from ENP's treatment-resistant patient study and what they mean for the future potential of TRP-8803. ... Read More The post Long Shortz with Entropy Neurodynamics: TRP-8803 shows encouraging early signal in binge eating disorder appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP) in Focus: Could This ASX Biotech Stock Be One to Watch in September 2026? Kalkine
The trial, being conducted in collaboration with Swinburne University of Technology, is evaluating whether the psychedelic treatment can deliver sustained ... Read More The post Entropy’s IV psilocin maintains binge-eating improvements for 12 weeks appeared first on Stockhead.
Entropy Neurodynamics reports “highly encouraging” follow-up results from its novel binge eating disorder (BED) trial using psychedelics. ... Read More The post Health Check: Entropy BEDs down durable response in binge-eating study appeared first on Stockhead.
Entropy Neurodynamics reports durable 12-week BED response from TRP-8803, with 50% binge-free and 73% weekly episodes below baseline after two doses.
other announcement
The new clinical study is a more controlled and scalable treatment model that could be significant for depression and broader ... Read More The post Long Shortz with Entropy Neurodynamics: New depression study puts psilocin therapy in focus appeared first on Stockhead.
Entropy Neurodynamics signs a pre-Clinical Trial Agreement with the University of California, San Francisco (UCSF) to undertake a Phase II ... Read More The post Entropy’s IV-psilocin candidate will go up against widely used antidepressant in proposed Phase II trial appeared first on Stockhead.
other announcement
The deal gives a key manufacturing base as it prepares for broader international trials, regulatory pathways and potential commercialisation. ... Read More The post StockTake: Entropy locks in BioCina for TRP-8803 GMP manufacturing appeared first on Stockhead.
other announcement
ENP's basket study will test TRP-8803 across multiple neuropsychiatric disorders in one clinical program. ... Read More The post Long Shortz with Entropy Neurodynamics: Treatment trial fast-tracked appeared first on Stockhead.
director_dealing announcement
ENP has signed an expanded clinical trial research agreement with Melbourne’s Swinburne University to conduct the study. ... Read More The post Entropy secures ethics approval for ‘world-first’ multi-indication psychedelic trial appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP): TRP-8803 Clinical Trial Advances Kalkine
other announcement
The patent titled Methods of Treating Fibromyalgia with Compositions Comprising Psilocybin, provides protection for the clinical use of psilocybin in ... Read More The post Entropy granted South African patent for psilocybin-based fibromyalgia treatment appeared first on Stockhead.
other announcement
TRP8803 used in trials to treat-resistant binge eating disorder why IV-delivered psilocybin approach could transform psychedelic medicine. ... Read More The post Long Shortz with Entropy Neurodynamics: Phase Two results exceed expectations appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP): Could These World-First IV Psilocin Results Be Breakthrough Moment? Kalkine
other announcement
Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic ... Read More The post Biocurious: Entropy surfs the supportive wave to psychedelic drug approval appeared first on Stockhead.
Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic ... Read More The post Biocurious: Entropy rides a supportive wave towards psychedelic drug approval appeared first on Stockhead.
Safety gatekeepers have cleared Entropy Neurodynamics to advance to the second cohort of its psilocin-assisted binge eating disorder study. ... Read More The post Ever so safely, Entropy can kick off second stage of groundbreaking binge eating trial appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP) Shares Slip Despite DSMB Safety Clearance — What Do Investors Need to Know? Kalkine
director_dealing announcement
other announcement
Phase 2a trial enrolled 12 patients who had failed multiple standard treatments. ... Read More The post Entropy Neurodynamics reports 75pc response rate in IBS trial appeared first on Stockhead.
Stockhead
ASX
Google News
Small Caps